"On Feb. 24, 2014, the U.S. Food and Drug Administration approved Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired "...
- Patient Information:
Details with Side Effects
No reports of overdosage with GlucaGen have been reported. If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.
GlucaGen is contraindicated in patients with:
- Known hypersensitivity to glucagon, lactose or any other constituent in GlucaGen
- Pheochromocytoma [see WARNINGS AND PRECAUTIONS]
- Insulinoma [see WARNINGS AND PRECAUTIONS]
Last reviewed on RxList: 1/13/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional GlucaGen Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and advances in treatment.